| 摘要: |
| 目的探讨结直肠癌患者中多配体蛋白聚糖-1（Syndecan-1)与表皮生长因子受体（EGFR）表达及鼠类肉瘤病毒癌基因（KRAS）突变的关系。方法选择原发性结直肠癌标本160例，结肠部肿瘤112例，直肠部肿瘤48例；病理类型为腺癌156例，其它病理类型4例。利用免疫组化法检测组织标本中Syndecan-1和EGFR的表达情况，运用直接测序法检测组织标本中KRAS基因外显子2第12、第13位密码子的突变状态。采用Spearman相关分析Syndecan-1的表达与EGFR表达及KRAS基因突变的关系。结果肿瘤标本中Syndecan-1表达阳性41例，主要位于细胞膜20例，主要位于细胞浆16例，细胞膜与细胞浆同时表达5例。EGFR在结直肠癌中的阳性表达率69.4%，所有结直肠癌患者中发生KRAS突变率为37.5%。Syndecan-1的表达在肿瘤区域淋巴结有无转移、有无远处转移中差异均无统计学意义（均P＞0.05）。Syndecan-1的表达与EGFR表达呈显著相关（r=1.488，P＜0.01），而与KRAS状态无相关性（r=9.278，P＞0.05）。结论Syndecan-1的表达可能对结直肠癌患者的进展及预后判断有一定价值。 |
| 关键词: 多配体蛋白聚糖 -1 表皮生长因子受体 鼠类肉瘤病毒癌基因 结直肠癌 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Expressions of Syndecan-1, EGFR and KRAS gene mutations in colorectal carcinoma |
|
YUAN Shaofei, ZHU Linjia, ZHENG Wei’e, ZHANG Wu, SUN Hongyu
|
|
the Third Affiliated Hospital of Wenzhou Medical University
|
| Abstract: |
| Objective To investigate the expression of Syndecan-1, EGFR and KRAS gene mutations in colorectal carcinoma. Methods The expressions of Syndecan-1 and EGFR were detected by immunohistochemistry in surgical specimens of 160 patients with primary colorectal carcinoma treated between 2009 and 2014 at our Hospital. DNA sequencing was used to detect mutations in KRAS (codons12,13 of exon2).The relationship between Syndecan-1 expression and various clinicopathological parameters and molecular markers was analyzed. Results There were 156(97.5%) cases of adenocarcinomas, and 4 (2.5%) cases of other pathological types. Syndecan-1 expression was identified in 41 (25.6%) colorectal cancer cases, among which 20 showed predominantly membranous immunopositivity, 16 showed a predominantly cytoplasmic staining, and 5 showed mixed membranous and cytoplasmic staining. The positive rate of EGFR expression was 69.4%, and KRAS mutations rate was 37.5% in 160 colorectal cancer cases. The expression of Syndecan-1 was significantly correlated with EGFR expression (r=1.488, P＜0.01), however, it was not correlated with KRAS mutations (r=9.278, P ＞0.05), lymph node metastasis and distant
metastasis (P ＞0.05). Conclusion The expression profile of Syndecan-1 may be of clinical value in colorectal cancer and may help in identifying aggressive forms of colorectal carcinoma. |
| Key words: Syndecan-1 EGFR KRAS Colorectal carcinoma |
